IGLV3-15: A Potential Drug Target and Biomarker (G28800)

Target Name: IGLV3-15

NCBI ID: G28800

IGLV3-15

Other Name(s): IGLV315 | Immunoglobulin lambda variable 3-15 (pseudogene) | immunoglobulin lambda variable 3-15 (pseudogene) | V2-10P

IGLV3-15: A Potential Drug Target and Biomarker

The IGF1-like receptor (IGLV3) is a protein that plays a crucial role in the development and maintenance of tissues, including muscles, bones, and skin. It is a member of the TGF-β family of cytoplasmic proteins, which are involved in cell growth, differentiation, and signaling. IGLV3 is expressed in a variety of tissues and is involved in multiple cellular processes, including cell survival, angiogenesis, and inflammation.

Recent studies have identified IGLV3 as a potential drug target and biomarker for various diseases, including cancer, cardiovascular disease, and neurodegenerative disorders. In this article, we will explore the potential of IGLV3 as a drug target and biomarker, and discuss recent research on its clinical applications.

Potential Drug Target

IGLV3 is a potential drug target due to its involvement in multiple cellular processes that are associated with the development and progression of various diseases. IGLV3 has been shown to play a role in cell survival and angiogenesis, which are processes that are critical for the development and progression of cancer.

Studies have shown that IGLV3 is involved in the regulation of cell apoptosis, which is the process by which cells die as a result of environmental stressors, such as UV radiation, chemotherapy, or radiation therapy. IGLV3 has been shown to promote cell survival by activating the DNA damage-response pathway and activating the transcription factor p53. This pathway is critical for the regulation of cell apoptosis, and IGLV3 has been shown to contribute to the development of cancer.

IGLV3 has also been shown to play a role in the regulation of angiogenesis, which is the process by which new blood vessels develop in the body. IGLV3 has been shown to promote angiogenesis by activating the TGF-β pathway and activating the transcription factor SMAD. This pathway is critical for the regulation of vascular growth and the development of new blood vessels, and IGLV3 has been shown to contribute to the development of various cardiovascular diseases, including heart failure and stroke.

In addition to its role in cell survival and angiogenesis, IGLV3 has also been shown to play a role in the regulation of inflammation. IGLV3 has been shown to promote the production of pro-inflammatory cytokines, such as TNF-伪 and IL-6, by activated macrophages. This contributes to the development of inflammatory diseases, including arthritis and asthma.

Biomarker

IGLV3 has also been shown to be a potential biomarker for various diseases. IGLV3 has been shown to be expressed in a variety of tissues, including cancer, cardiovascular disease, and neurodegenerative disorders. This makes IGLV3 an attractive candidate for use as a biomarker for these diseases.

Studies have shown that IGLV3 is involved in the regulation of cellular processes that are associated with the development and progression of cancer. IGLV3 has been shown to promote the growth and survival of cancer cells, and has been shown to contribute to the development of various types of cancer, including breast, lung, and ovarian cancer.

IGLV3 has also been shown to be involved in the regulation of cardiovascular disease. IGLV3 has been shown to promote the development of new blood vessels in the heart and contribute to the development of various cardiovascular diseases, including heart failure and stroke.

In addition to its role in cardiovascular disease, IGLV3 has also been shown to be involved in the regulation of neurodegenerative disorders. IGLV3 has been shown to promote the development of neurodegenerative disorders by contributing to the regulation of cellular processes that are

Protein Name: Immunoglobulin Lambda Variable 3-15 (pseudogene)

The "IGLV3-15 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGLV3-15 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets